source
- Novartis IL-6 antibody pacibekitug cuts inflammation markers in Phase 2 studyA Phase 2 trial called TRANQUILITY showed that pacibekitug, an IL-6‑targeting antibody acquired by Novartis, reduced several biomarkers of inflammation in participants. The reductions were sustain…
- AstraZeneca’s ATTR-CM Silencer Trial Fails to Show Benefit Over Existing Stabilizer TherapyAstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoints. The study showed no additional clinical benefi…